Human Immunodeficiency Virus2 Reverse Transcriptase
recombinant, E. coli
For in vitro use only!
Shipping: shipped on dry ice
Storage Conditions: store at -80 °C
avoid freeze/thaw cycles
Shelf Life: 12 months
Molecular Weight: α: 68 kDa, β: 54 kDa
Purity: > 95 % (SDS-PAGE)
Form: liquid (Supplied in 20 mM Tris-HCl pH 7.8, 1 mM DTT, 1 mM EDTA, 15% glycerol and 0.2% BSA)
Activity: 10.000 U/mg (1 unit is defined as the amount of enzyme that incorporates 1.0 nmol of dTTP into acid-insoluble products in 10 min at 37°C)
HIV-2 reverse transcriptase (RT) is used by the Human Immunodeficiency Virus-1 to transcribe its RNA genome into single-stranded DNA. HIV-2 RT can be used for incorporation of nucleotide analogs into DNA by RT-PCR or as a standard for assaying HIV-2 RT activity in human serum. In contrast to HIV-1 RT, HIV-2 RT is not inhibited by nonnucleoside RT inhibitors (NNRTI's).
Gleenberg et al. (2005) Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase. J. Biol. Chem. 280:21987.
Pata et al. (2002) Assembly, purification and crystallization of an active HIV-1 reverse transcriptase initiation complex. Nucl. Acids Res. 30:4855.
Divita et al. (1995) Dimerization Kinetics of HIV-1 and HIV-2 Reverse Transcriptase - A two step process. J. Mol. Biol. 245:508.
Mansky et al. (2002) Influence of reverse transcriptase variants, drugs, and Vpr on human immunodeficiency virus type 1 mutant frequencies. J. Virol. 77:2071.
Larder et al. (1999) Closing in on HIV drug resistance. Nature Structural Biology 6:103.
Ren et al. (2002) Structure of HIV-2 reverse transcriptase at 2.35 Å resolution and the mechanism of resistance to non-nucleoside inhibitors. PNAS 99:14410.